Clinical trials: Hematological Neoplasms
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cancer, Lung Cancer
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
Optimal patient-centered care is often not being delivered to cancer patients, especially to vulnerable populations like those living in underserved rural areas.
- Conditions
- Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
- Trial name
- PRISMA (NCT07788729)
- Testing
- PRISMA-interventions
- Where
- 8 sites in Germany
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- University of Regensburg
Invasive Fungal Disease, Chronic Disseminated Candidiasis
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
- Conditions
- Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation
- Trial name
- CANHPARI (NCT01916057)
- Testing
- 18F-FDG PET Scan
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hematological Malignancy
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.
- Trial name
- NCT06586671
- Testing
- Nemtabrutinib
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Solid and Hematological Malignancies
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
This is a two-part, open-label, randomized, crossover study in healthy subjects (vasectomized males and women of non-childbearing potential), performed at 2 study centers
- Trial name
- NCT04944771
- Testing
- Capivasertib, Rabeprazole
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19, Healthy Volunteers
Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System
Determination of both the degree and duration of the immunity provided after receiving the BNT162b2 vaccine against SARS-Cov-2.
- Conditions
- COVID-19, Healthy Volunteers, Chronic Disease, Hematological Malignancies
- Trial name
- NCT04743388
- Testing
- BNT162b2, Other vaccine against SARS-Cov-2
- Where
- Greece
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Hematological Malignancies
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
The present project aims at comparing two nonmyeloablative regimens currently used in 2 major HCT centers in the US for patients with HLA-matched related or unrelated donor: the one from the Seattle group consisting of 2 Gy TBI…
- Trial name
- NCT00603954
- Testing
- Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8 Gy) + ATG
- Where
- 11 sites in Belgium, Netherlands
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Liege
Hematological Malignancy
Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers
This study will address whether teaching the Body Scan exercise to cancer patients with hematological malignancies and their caregivers during an inpatient hospitalization improves reported physical and psychological symptoms…
- Trial name
- NCT03611764
- Testing
- Body Scan, Rotterdam Symptom Checklist, Practice Logs
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hematological Malignancies, Cancer
Cologne Cohort of Neutropenic Patients (CoCoNut)
The Cologne Cohort of Neutropenic Patients (CoCoNut) is a non-interventional cohort study assessing risk factors, interventions, and outcome of immunosuppressed patients with or without opportunistic infections.
- Conditions
- Hematological Malignancies, Cancer, Chemotherapy, Neutropenia
- Trial name
- CoCoNut (NCT01821456)
- Testing
- Antiinfectives
- Where
- Germany
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- University Hospital of Cologne
Pediatric Solid Malignancies, Pediatric Hematological Malignancies
Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy and Their Role in Antitumor Activity
Examine neutrophil extracellular traps (NETs) formation, in relation to other neutrophil functions like chemotaxis, superoxide production, hydrogen peroxide production, and the presence of myeloperoxidase, in pediatric patients…
- Trial name
- NCT01533779
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hematological Malignancies
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot…
- Trial name
- NCT00504803
- Testing
- Mesenchymal stem cell infusion
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Liege